Method for the diagnosis or prognosis, in vitro, of prostate cancer
AssigneeHospices Civils De Lyon
InventorsFrançois Mallet, Nathalie Mugnier, Philippe Perot
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for the in vitro diagnosis or prognosis of prostate cancer, which includes a step of detecting at least one expression product of at least one HERV nucleic acid sequence, the use of said nucleic acid sequences, once isolated, as one or more molecular marker(s) and a kit comprising at least one specific binding partner of at least one of the expression products of the HERV nucleic acid sequences.
Claims18
A method for the in vitro diagnosis or prognosis of prostate cancer in a biological sample taken from a patient, which comprises a step of detecting at least two expression products respectively of at least two nucleic acid sequences, said nucleic acid sequences being chosen from the sequences identified in SEQ ID NOs:
- 1 to 75 or from the sequences which exhibit at least 99% identity with one of the sequences identified in SEQ ID NOs:
- 1 to 75.
A method for in vitro diagnosis or prognosis of prostate cancer comprising at least two nucleic acid sequences, once isolated, the two nucleic acid sequences consist of:
- (i) at least two DNA sequences chosen from the sequences SEQ ID NOs:
- 1 to 75, or
- (ii) at least two DNA sequences respectively complementary to at least two sequences chosen from the sequences SEQ ID NOs:
- 1 to 75, or
- (iii) at least two DNA sequences which exhibit at least 99% identity with two sequences as defined in (i) and (ii), or
- (iv) at least two RNA sequences which are respectively the transcription product of two sequences chosen from the sequences as defined in (i), or
- (v) at least two RNA sequences which are the transcription product of at least two sequences chosen from the sequences which exhibit at least 99% identity with the sequences as defined in (i).
A kit for the in vitro diagnosis or prognosis of prostate cancer in a biological sample taken from a patient, which comprises at least two respectively specific binding partners of at least two expression products of at least two nucleic acid sequences chosen from the sequences identified in SEQ ID NOs:
- 1 to 75 or from the sequences which exhibit at least 99% identity with the nucleic acid sequences identified in SEQ ID NOs:
- 1 to 75 and no more than 75 specific binding partners of the expression products of the nucleic acid sequences identified in SEQ ID NOs:
- 1 to 75 or of the nucleic acid sequences which exhibit at least 99% identity with the nucleic acid sequences identified in SEQ ID NOs:
- 1 to 75.
A method for evaluating the efficacy of a treatment and/or a progression in prostate cancer, which comprises a step of detecting at least two expression products respectively of at least two nucleic acid sequences, said two nucleic acid sequences being chosen from the sequences identified in SEQ ID NOs:
- 1 to 75 or from the sequences which exhibit at least 99% identity respectively with the sequences identified in SEQ ID NOs:
- 1 to 75.
Dependencies are inferred from the claim text.